Kyrillus Shohdy, MD

A previously unrecognized estrogen-dependent signaling pathway in the gut regulates visceral pain sensitivity in mice, according to a new Science study. The findings provide a pathway toward targeted therapeutic strategies. 📄: scim.ag/4rTYSz4 #SciencePerspective: scim.ag/4j8UAA6

Cancer cell plasticity and resistance to KRAS inhibition Two recent preclinical examples in #ColorectalCancer @CD_AACR aacrjournals.org/cancerdiscover… @Cancer_Cell cell.com/cancer-cell/fu…

🔥off the press🔥 Cholangiocarcinoma 2026: status quo, unmet needs and priorities @NatRevGastroHep doi.org/10.1038/s41575… 👉get the lastest, most comprehensive summary on cholangiocarcinoma 👏fantastic team effort! @myESMO @EASLedu @ILCAnews

How can a gene mutation be present throughout the body yet cause cancer only in certain tissues? This is exactly the challenge our SPECIFICANCER team took on 7 years ago. Read the newly published impact report from the team that reshaped our understanding of tissue specificity to pioneer potential new cancer treatments. Thank you to everyone involved for driving this ambitious science forward. Thanks also to our co-funders, @TheMarkFdn, for supporting the #CancerGrandChallenges SPECIFICANCER team and global science. Read the report: lnkd.in/eDrQ9guu

Systemic review on neurocognitive outcomes in patients with🧠 metastases in @TheLancetOncol Urgent need for research assessing modality-specific neurocognitive tox and optimal sequencing of therapies! @OncoAlert #brainmets thelancet.com/journals/lanon…

What’s true in #PancreaticCancer precursor lesions is also true in #ColorectalCancer precursor lesions. @cncurtis @SnyderShot @StanfordMed demonstrate polyclonal origin of adenomas in patients with FAP. Cancer as a manifestation of convergent evolution! nature.com/articles/s4158…

Groundbreaking work just came today from  @owen_sansom Lab, spearheaded by Mark White and exceptionally talented team @CRUKScotland & @UoFGlasgow The work unmasked MAPK-driven Colorectal Cancer's clever escape from therapy. Yes Always search for the WNT.  nature.com/articles/s4158…

Very proud of all our hardwork! Exciting new paper exploring the origin of liver cancer nature.com/articles/s4158… @owen_sansom

Paneth-like transition drives resistance to dual targeting of KRAS & EGFR in CRC ✅CRC cells surviving combined KRAS & EGFR inhibition acquire Paneth-like state ✅SMAD1-FGFR3 axis triggers Paneth-like plasticity ✅FGFR3 blockade could overcome plasticity-driven drug tolerance @OncoAlert @Cancer_Cell cell.com/cancer-cell/fu…

Provocative new data in @NatureMedicine from @JenWargoMD @nadim_ajami & colleagues @MDAndersonNews Microbial signals in primary and metastatic brain tumors nature.com/articles/s4159… Orthogonal validation using multiple platforms provides support for this observation

📌Inaccurate lymph node clinical staging in early and intermediate-risk rectal cancer @EORTC 🚨19.5% understaged and 62.4% overstaged ✅Seems no survival effect ➡️At least a destressing data when MRI shows 1-3 small lymph nodes that we can not decide whether pathologic or not 👉ejcancer.com/article/S0959-… #cancer #oncology #MedX #rectal @OncoAlert @realbowtiedoc @GIMedOnc

ANOVA in R! 💪 in ONE LINE OF CODE! ggstatsplot::ggbetweenstats(ISLR::Wage, race, wage) Watch the video for more details: youtu.be/JDGtLG0Tceo #rstats #statistics #dataanalysis #stats #datascience #r4ds

🍽️ Turning “no appetite” into “pass the plate” with olanzapine 📝 JNCCN 2025 | OlAnCa trial | DB RCT | n=164 | Cairo Univ 🔑 Trial essentials • 🌐 Incurable solid tumors + cachexia • 🎲 Randomized: Olanzapine 5 mg QHS vs placebo • 🎯 Primary: Appetite (ESAS-Anorexia) @ 1 wk 📊 Results 🍴 Appetite ↑ more with olanzapine (–2 vs –1; p=0.003) ⚖️ ≥5% weight gain: 14% vs 0% (p=0.008) 😀 QoL (FAACT-ACS) improved 💪 BUT ↓ handgrip strength (–2.8 kg) & ↑ grade ≥3 anemia/leukopenia 💡 Takeaway Olanzapine 5 mg = rapid appetite & weight gains in cachexia — but ⚠️ safety & durability remain open questions. 📓Othman NO, et al. JNCCN. 2025;23(9):385–392. 🔗DOI: jnccn.org/abstract/journ… #OncoTwitter #MedTwitter #PalliativeCare #Cachexia @OncoAlert @myesmo @asco @JNCCN

#USCAP2025 w/ Dr Voltaggio Esophageal ⬆️ grade dysplasia/intramucosal adeno → treated with EMR. Presence of muscularis mucosa = lateral margin; large vessels + loose CT = deep margin. Recommendation to pin specimen before fixing for easier margin assessment. #PathWebinarPearls

New review: Mellor, Larson, and @DrMengWang discuss the molecular mechanisms of mammalian genomic instability arising from folate deficiency and how this impacts genome biology in health and disease. hubs.la/Q03D97r20 #CellMetabolism

New Paper Alert: BRCA1/2 Mutations and RB1 Alterations Predict Poorer Outcomes With Endocrine Therapy ± CDK4/6 Inhibitors in HR+/HER2– Breast Cancer Authors: Hamdy A. Azim, Hagar Elghazawy (@HagarElghazawy1), Kyrillus S. Shohdy (@Kyrillus2 ) Shaimaa Lasheen, Mahmoud Elghazawy, Ramy Ghazy, Dalia Abdelnasser, Loay Kassem (@L0AY_Kassem) oncodaily.com/new-paper-aler… #Cancer #Oncology #OncoDaily #Health #Medicine @CancerWorldmag

Here is a video on management of 4 common lower GI radiotherapy toxicities: 1. Radiation dermatitis 2. Diarrhea 3. Acute RT proctitis 4. Late/chronic RT proctitis Hope it is helpful! Full video (16 min) & slides 🧵 thread below. 1/X

Olanzapine for Anorexia in Patients With Incurable #Cancer and #Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. jnccn.org/view/journals/… @JNCCN @CancerCachexia #CancerResearch #PallOnc #SuppOnc #CancerCare

@mgoudaMD Congrats 😊😊

Effective today, I am starting a new role as an Assistant Professor of Medical Oncology at MD Anderson Cancer Center. My primary clinical focus will center on treating patients with melanoma; while continuing research aimed at advancing liquid biopsy and drug development in the field. I am deeply grateful to my mentors, colleagues, and —above all — my family for their unwavering support throughout my career journey. Exciting years ahead as we fight to #EndCancer! #Making_Cancer_History

@NadiaNasreddin Thanks Nadia.

Our study is out @ESMO_Open. The largest cohort from Northern African background on BRCA1/2 genetics. So pleased to lead such work that bridges the equity gap in precision oncology.